Evidence map›Paper›PMID 34867933›Full record

ArticleFrontiers in immunology2021

Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities.

Chang-Feng Chu, Florian Sabath, Silvia Fibi-Smetana, Shan Sun, Rupert Öllinger, Elfriede Noeßner, Ying-Yin Chao, Linus Rinke, Elena Winheim, Roland Rad and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Chang-Feng ChuInstitute of Virology, Technical University of Munich, Munich, Germany.
Florian SabathCentral Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.
Silvia Fibi-SmetanaInstitute of Biomedical Informatics, Graz University of Technology, Graz, Austria.
Shan SunInstitute of Virology, Technical University of Munich, Munich, Germany.
Rupert ÖllingerCentral Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.
Elfriede NoeßnerImmunoanalytics-Tissue Control of Immunocytes, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.
Ying-Yin ChaoInstitute of Virology, Technical University of Munich, Munich, Germany.
Linus RinkeInstitute for Immunology, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians-University Munich, Planegg-Martinsried, Germany.
Elena WinheimInstitute for Immunology, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians-University Munich, Planegg-Martinsried, Germany.
Roland RadCentral Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.
Anne B KrugInstitute for Immunology, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians-University Munich, Planegg-Martinsried, Germany.
Leila TaherInstitute of Biomedical Informatics, Graz University of Technology, Graz, Austria.
Christina E ZielinskiInstitute of Virology, Technical University of Munich, Munich, Germany.
Technical University of Munich · DELudwig-Maximilians-Universität München · DEGraz University of Technology · ATHelmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, the disease caused by SARS-CoV-2 infection, can assume a highly variable disease course, ranging from asymptomatic infection, which constitutes the majority of cases, to severe respiratory failure. This implies a diverse host immune response to SARS-CoV-2. However, the immunological underpinnings underlying these divergent disease courses remain elusive. We therefore set out to longitudinally characterize immune signatures of convalescent COVID-19 patients stratified according to their disease severity. Our unique convalescent COVID-19 cohort consists of 74 patients not confounded by comorbidities. This is the first study of which we are aware that excludes immune abrogations associated with non-SARS-CoV-2 related risk factors of disease severity. Patients were followed up and analyzed longitudinally (2, 4 and 6 weeks after infection) by high-dimensional flow cytometric profiling of peripheral blood mononuclear cells (PBMCs), in-depth serum analytics, and transcriptomics. Immune phenotypes were correlated to disease severity. Convalescence was overall associated with uniform immune signatures, but distinct immune signatures for mildly

Indexed as

AdultAgedAged, 80 and overConvalescenceCOVID-19FemaleHumansImmunophenotypingMaleMiddle AgedSARS-CoV-2Severity of Illness IndexYoung AdultCOVID-19disease severity assessmentimmunomonitoringSARS-CoV-2T cells

Identifiers

PMID34867933
PMCPMC8634761
OpenAlexW3196022501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.